Akari Therapeutics plc held its Annual General Meeting on June 30, 2025. Shareholders approved an increase in the number of shares available for the grant of awards under the 2023 Equity Incentive Plan. Additionally, a proposal was passed authorizing directors to allot shares and grant rights to subscribe for or convert any security into shares up to an aggregate nominal amount of USD 20,000,000, with this authority expiring on June 30, 2030. A related proposal empowering directors to allot equity securities for cash as if pre-emption provisions did not apply was also approved, with this empowerment expiring five years after the resolution date.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akari Therapeutics plc published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0000950170-25-092350), on July 01, 2025, and is solely responsible for the information contained therein.